Gemini quaternary ammonium compound PMT12-BF4 inhibits *Candida albicans* via regulating iron homeostasis

Li-Hang Hsu¹, Dobrawa Kwaśniewska², Shih-Cheng Wang¹, Tang-Long Shen¹, Daria Wieczorek²* & Ying-Lien Chen²*¹

Quaternary ammonium compounds (QACs) are classified as cationic surfactants, and are known for their biocidal activity. However, their modes of action are thus far not completely understood. In this study, we synthesized a gemini QAC, PMT12-BF4 and found that it exerted unsurpassed broad-spectrum antifungal activity against drug susceptible and resistant *Candida albicans*, and other pathogenic fungi, with a minimal inhibitory concentration (MIC) at 1 or 2 μg/mL. These results indicated that PMT12-BF4 used a mode of action distinct from current antifungal drugs. In addition, fungal pathogens treated with PMT12-BF4 were not able to grow on fresh YPD agar plates, indicating that the effect of PMT12-BF4 was fungicidal, and the minimal fungicidal concentration (MFC) against *C. albicans* isolates was 1 or 2 μg/mL. The ability of yeast-to-hyphal transition and biofilm formation of *C. albicans* was disrupted by PMT12-BF4. To investigate the modes of action of PMT12-BF4 in *C. albicans*, we used an RNA sequencing approach and screened a *C. albicans* deletion mutant library to identify potential pathways affected by PMT12-BF4. Combining these two approaches with a spotting assay, we showed that the ability of PMT12-BF4 to inhibit *C. albicans* is potentially linked to iron ion homeostasis.

*Candida albicans* is an opportunistic fungal pathogen causing candidiasis mainly in immunocompromised individuals with candidemia, or superficial infections such as oral thrush and vaginal infections. To date, polyenes, azoles, and echinocandins are the dominant antifungal classes used to cure candidiasis. However, increased incidence of drug resistance has reduced the efficacy of drugs in these classes, indicating an urgent need to develop antifungal agents to combat drug-resistant *C. albicans*.

Simple surfactants whose structures are based on quaternary ammonium compounds (QACs) are usually made of a positive nitrogen atom with four substituents attached to the nitrogen atom, at least one of which is a long alkyl chain. QACs have many applications, for example in anesthesiology, dentistry, ophthalmology, and asthma. A single range of applications is directly related to their biocidal activity. QACs have biocidal activity not only against Gram-positive and Gram-negative bacteria but also against fungal pathogens. However, there are limited studies on gemini surfactants derived from QACs. Gemini surfactants are made of two polar heads separated by a spacer. Polar heads can have a positive charge when synthesized from quaternary ammonium salts, and they can be substituted with alkyl chains called tails. With the presence of hydrophobic rigid or flexible spacers and two identical or different hydrophilic heads, it becomes possible to synthesize dimeric surfactants with diverse structures.

Gemini surfactants have significantly higher surface activity compared to conventional analogues. The reason for the increased activity of gemini surfactants is the larger total number of carbon atoms in the hydrophobic chains. Moreover, their biocidal properties are noteworthy and characterized by a broad spectrum of antimicrobial activity. However, the potential mechanisms that gemini QACs use to target pathogens remains unknown.

In this study, we demonstrated that a newly synthesized gemini QAC, 1, 5-bis(dodecyl)-1, 1, 3, 5-pentamethyl-3-aza-1, 5-pentanedi ammonium ditetrafluoroborate (PMT12-BF4), possesses novel fungicidal

¹Department of Plant Pathology and Microbiology, National Taiwan University, 10617, Taipei, Taiwan. ²Department of Technology and Instrumental Analysis, Poznan University of Economics and Business, Poznan, Poland. *email: Daria.wieczorek@ue.poznan.pl; ychen28@ntu.edu.tw
activity against a broad spectrum of fungal pathogens including drug-resistant \textit{C. albicans}. The hyphal growth and biofilm formation of \textit{C. albicans} were reduced after PMT12-BF4 treatment, and the mode of action of this compound was potentially associated with iron ion homeostasis based on RNA sequencing, mutant library screening, and spotting assays.

**Results**

**Synthesized surfactants exhibited a broad spectrum of antifungal activity.** Two gemini QACs (PMT12-BF4 and PMT16-BF4) were synthesized (Fig. 1) to test antifungal activity against clinical drug-susceptible and -resistant \textit{C. albicans} isolates, and multiple fungal pathogens (Table 1). PMT12-BF4 with 12 carbons in the alkyl chain exhibited novel antifungal activity against \textit{C. albicans} SC5314 with MIC = 1 μg/mL, as well as drug-resistant 12–99 and 89 isolates with MIC = 1 μg/mL (Table 2). In addition, PMT12-BF4 was also effective against non-\textit{albicans} \textit{Candida} species including \textit{C. tropicalis} MYA3404 (2 μg/mL) and \textit{C. glabrata} CBS138 (1 μg/mL), and other human or plant pathogenic fungi such as \textit{Cryptococcus neoformans} H99 (1 μg/mL), \textit{Aspergillus fumigatus} AF293 (2 μg/mL), \textit{Fusarium oxysporum} FOSC3-a (2 μg/mL), and \textit{Fusarium oxysporum} f. sp. \textit{lycopersici} 4287 (2 μg/mL) (Table 2). In contrast, the analogue PMT16-BF4 which possessed an alkyl chain with 16 carbons was not effective against \textit{C. albicans} (MIC > 64 μg/mL) (Table 2), indicating the critical role of the length of the alkyl chain in gemini QACs.

Interestingly, not all fungal pathogens tested showed similar susceptibility to PMT16-BF4. \textit{C. glabrata} CBS138 and \textit{C. neoformans} H99 showed higher susceptibility (MIC = 4 μg/mL) to this compound. Moreover, growth of \textit{F. oxysporum} f. sp. \textit{lycopersici} 4287, \textit{F. oxysporum} and \textit{A. fumigatus} AF293 was also inhibited by

**Figure 1.** Diagram of the synthesis reactions of PMTX-BF4 compounds. (a) PMTX was synthesized as a result of the reaction of a tertiary amine (N, N', N', N'- Pentamethyldiethylenetriamine) with an alkyl bromide. (b) PMTX-BF4 was synthesized after ion exchange reaction of PMTX and tetrafluoroboric acid.

| Strains | Description | Reference |
|---------|-------------|-----------|
| \textit{Candida albicans} SC5314 | clinical isolate | 31 |
| \textit{Candida albicans} 12–99 | clinical fluconazole resistant | 32 |
| \textit{Candida albicans} 89 | clinical echinocandin resistant | 33 |
| \textit{Candida tropicalis} MYA3404 | clinical isolate | 34 |
| \textit{Candida glabrata} CBS138 | clinical isolate | 35 |
| \textit{Cryptococcus neoformans} H99 | clinical isolate | 36 |
| \textit{Malassezia furfur} BCRC22950 | clinical isolate | 37 |
| \textit{Aspergillus fumigatus} AF293 | clinical isolate | 38 |
| \textit{Fusarium oxysporum} FOSC3-a | clinical isolate | 39 |
| \textit{Fusarium oxysporum} f. sp. \textit{lycopersici} 4287 | tomato isolate | 40 |

**Table 1.** Fungal pathogens used in this study.
There was a reduction in biofilm formation after the addition of PMT12-BF4 at 2 or 4 μg/mL in C. albicans. Biofilm formation at 4 °C showed up and down during the wash step (Fig. 4A). The fluconazole-resistant isolate 12–99 only showed reduced biofilm formation at 4 °C compared with the control group (Fig. 4A). The fungicidal activity of PMT12-BF4 against C. albicans was further confirmed by time-killing assays. The number of colony forming units (CFUs) decreased >99% compared to initial inoculum after 48 h incubation at 4 μg/mL PMT12-BF4 (Fig. 4B).

PMT12-BF4 reduced yeast-to-hyphae transition in C. albicans. The ability to undergo yeast-to-hyphae transition is a critical virulence factor in C. albicans. To determine this ability in C. albicans, cultures were grown overnight in YPD, washed twice with ddH2O, and incubated at 37 °C with RPMI 1640 medium to induce hyphal development. The length of germ tubes decreased after 3 h incubation in the presence of 0.25 μg/mL PMT12-BF4 (Fig. 3A). Moreover, cells exposed to PMT12-BF4 at 2 μg/mL showed wrinkled cell surfaces and even broken cells under SEM observation (Fig. 3B).

PMT12-BF4 interfered with C. albicans biofilm formation. The ability of C. albicans to form a biofilm is usually linked to drug tolerance. We thus tested PMT12-BF4 interference of biofilm formation in C. albicans. There was reduction in biofilm formation after addition of PMT12-BF4 at 2 or 4 μg/mL in drug-susceptible strain SC5314 and echinocandin-resistant isolate 89, and the biofilm structure could be easily removed by gently pipetting up and down during the wash step (Fig. 4A). The fluconazole-resistant isolate 12–99 only showed reduced biofilm formation at 4 μg/mL PMT12-BF4 (Fig. 4A). In summary, the biofilm formation was decreased by more than 50% with treatment with PMT12-BF4 at 4 μg/mL in three C. albicans strains (SC5314, 12–99, and 89) as compared with the control group (Fig. 4B).

Genome-wide analysis of PMT12-BF4-mediated genes in C. albicans. To investigate PMT12-BF4-mediated genes, we performed transcriptome analysis. We extracted C. albicans RNA in the presence or absence of PMT12-BF4 at 1 μg/mL for RNA sequencing experiments. RNAs extracted from cultures in fresh YPD medium were set as a control group for further fold-change analysis. Results of RNA sequencing revealed that transcriptome expression of cultures treated with PMT12-BF4 showed 42 differentially expressed genes (DEGs; \( P < 0.05 \)). In the presence of PMT12-BF4, 34 genes were up-regulated with a log fold-change ranging from 2 to 9.76, and 22 of the genes have been characterized. On the other hand, 8 genes were down-regulated with a log fold-change ranging from 2 to 3.73, and all of them have been characterized. Relative expression of 3 up- and 3 down-regulated genes was confirmed by qRT-PCR (Fig. 5). Gene ontology of characterized genes found that up-regulated genes were mainly involved in oxidizing metal ions, ferric-chelate reductase activity, iron ion transmembrane transporter, and oxidoreductase activity, while down-regulated genes were mainly involved in oxidoreductase activity, vitamin binding and coenzyme binding (Table 3).

To identify potential target(s) affected by PMT12-BF4 in C. albicans, we screened a deletion mutant library comprising of 666 homozygous mutants\(^{13}\). Three hundred and nine out of 666 mutants showed resistance (MIC >4 μg/mL) to PMT12-BF4, and among them the functions of 139 genes were characterized and described in the Candida Genome Database (CGD) website (http://www.candidagenome.org/). Among 139 genes, 29 (20.9%) genes were involved in iron-mediated regulation or iron-related functions, 34 (24.5%) genes were involved in hyphal growth, biofilm formation, or cell wall-related functions and the remaining genes were responsible for other functions (Supplementary Table 1).

### Table 2. MICs and MFCs (μg/mL) of PMT12-BF4 and PMT16-BF4 against fungal pathogens. MIC: minimum inhibitory concentration; MFC: minimum fungicidal concentration.

| Pathogen                  | PMT12-BF4 | PMT16-BF4 |
|---------------------------|-----------|-----------|
| C. albicans SC5314        | 1         | 1         |
| C. albicans 12–99         | 1         | 1         |
| C. albicans 89            | 1         | 1         |
| C. tropicalis MYA3404      | 2         | 2         |
| C. glabrata CBS138        | 1         | 1         |
| Cr. neoformans H99        | 1         | 1         |
| M. furfur BCRC22950       | >64       | >64       |
| A. fumigatus AF293         | 2         | 2         |
| F. oxysporum FOSC3-a      | 2         | 2         |
| F. oxysporum f. sp. lycopersici 4287 | 2 | 2 | 4 | >64 |

PMT16-BF4. Interestingly, the dandruff borne fungus, Malassezia furfur, was resistant to both PMT12-BF4 and PMT16-BF4 (i.e., MIC >64 μg/mL), indicating the compound’s target(s) in M. furfur might be distinct from other compound-susceptible fungi (Table 2).

| Pathogen                  | MIC  | MFC  |
|---------------------------|------|------|
| C. albicans 12–99         | >64  | >64  |
| C. albicans SC5314        | >64  | >64  |
| M. furfur BCRC22950       | >64  | >64  |
| A. fumigatus AF293         | 2    | 2    |
| F. oxysporum FOSC3-a      | 2    | 2    |
| F. oxysporum f. sp. lycopersici 4287 | 2 | 2 | 4 | >64 |

To identify potential target(s) affected by PMT12-BF4 in C. albicans, we screened a deletion mutant library comprising of 666 homozygous mutants\(^{13}\). Three hundred and nine out of 666 mutants showed resistance (MIC >4 μg/mL) to PMT12-BF4, and among them the functions of 139 genes were characterized and described in the Candida Genome Database (CGD) website (http://www.candidagenome.org/). Among 139 genes, 29 (20.9%) genes were involved in iron-mediated regulation or iron-related functions, 34 (24.5%) genes were involved in hyphal growth, biofilm formation, or cell wall-related functions and the remaining genes were responsible for other functions (Supplementary Table 1).
In a comparison of RNA sequencing and mutant library screening results, 6 genes (CFL2, FET3, XOG1, IFD6, RBT4 and BRG1) were up-regulated in the presence of PMT12-BF4, and their corresponding mutants were found to be resistant to PMT12-BF4 (Table 3 and Supplementary Table 1). Among these genes, 5 of 6 genes (CFL2, FET3, XOG1, RBT4, BRG1) were iron-related, while IFD6 was associated with biofilm formation.

Iron ions abolished the antifungal activity of PMT12-BF4. Our experimental results from RNA sequencing and mutant library screening revealed that iron ions may play a role in PMT12-BF4 antifungal activity, and thus a spotting assay was performed to investigate the impact of iron ions on antifungal activity of PMT12-BF4. Three C. albicans including drug-susceptible and -resistant isolates grew normally on a YNB agar plate, but growth significantly decreased after PMT12-BF4 was added (Fig. 6). Surprisingly, C. albicans isolates could be recovered from this condition after the addition of Fe2+, an absorbable form of iron ions for C. albicans. Meanwhile, similar results were seen when compared to the YNB agar plates containing ciclopirox olamine, an iron ion chelator, indicating that PMT12-BF4 may function in a similar manner to the iron ion chelator and interrupt the absorption of iron ions in C. albicans (Fig. 6).

PMT12-BF4 exhibited moderate toxicity to human cell lines. To determine the cytotoxicity of PMT12-BF4 against the human neuroblastoma cell line SK-N-SH and human embryonic kidney cell line HEK293, MTT reduction assays were conducted, and cell viability was determined after PMT12-BF4 treatment. Cell viability of both cell lines decreased as the concentration of PMT12-BF4 increased. The viability of SK-N-SH cells was lower than 50% at 5 μg/mL (45.85%) PMT12-BF4, while that of HEK293 was lower than 50% at 10 μg/mL (32.38%) PMT12-BF4. According to the equation obtained from linear regression analysis, the IC50 of PMT12-BF4 against SK-N-SH cells was 6.78 μg/mL, and that against HEK293 was 10.05 μg/mL (Fig. 7).

Discussion

A previous study showed that gemini surfactants inhibited bacterial pathogens especially Gram positive strains through their surfactant activity and the specific cell wall construction of the pathogens. However, few studies have discussed the activity of gemini QACs against fungal pathogens, and so far no clear mode of action has been proposed. In this study, we found that newly synthesized PMT12-BF4 had broad-spectrum fungicidal activity, especially combating drug-resistant C. albicans, suggesting PMT12-BF4 uses a mode of action distinct from current antifungal drugs. Although PMT12-BF4 exhibited antifungal activity to most fungal pathogens tested, M. furfur was resistant to PMT12-BF4, indicating that it is not a general biocidal compound and M. furfur might use specific detoxification system(s) to reduce the damage caused by PMT12-BF4.

The finding that the length of the hydrocarbon chain is associated with the strength of antimicrobial activity is of interest. Bao et al. demonstrated that the hydrocarbon lengths of the side chains in QACs could decrease the
Critical microcell concentration (CMC), but the antimicrobial activity against multiple pathogenic bacteria was similar among various QACs. Thus, longer or shorter hydrocarbon chains of QACs are not beneficial to inhibition of the microbes. Another study showed that a histidine-based surfactant could inhibit several Gram-positive and -negative bacteria as well as C. albicans, and their antimicrobial activity changed as the alkyl chain length changed. The most active compound was found in DMHNHC14, a C14 homologue. This surfactant possessed selective activity towards bacterial membranes, and had low toxicity to erythrocytes.

Figure 3. PMT12-BF4 inhibits C. albicans from germination. (A) C. albicans SC5314 overnight culture was diluted with 1 mL RPMI 1640 medium to OD600 0.25, and PMT12-BF4 was added at the indicated concentrations. After incubation for 3 h at 37°C, cells were observed with an optical microscope at 400×. Scale bar = 20 μm. (B) C. albicans overnight culture was diluted with 3 mL RPMI 1640 medium to 10^6 CFU/mL, and PMT12-BF4 was added at the indicated concentrations. After incubation for 3 h at 37°C, cells were pre-fixed with 2% glutaraldehyde, washed with PBS, pro-fixed with 1% OsO4, and dehydrated with a series of ethanol washes. Cells were dried with a critical point dryer. Gold was coated on samples before scanning electron microscopic observation. Scale bar = 5 μm.

Figure 4. PMT12-BF4 interferes with biofilm formation of drug-resistant C. albicans isolates. (A) Overnight culture was diluted with Spider medium to 0.5 OD600, and PMT12-BF4 was added after 2 h incubation at 37°C for cell adhesion at the indicated concentrations. Crystal violet staining and EtOH destaining were carried out after 24 h for biofilm formation. (B) A statistical diagram of (A) from 3 replicates. The OD595 was measured after destaining, and wells without PMT12-BF4 were set as 100% biofilm formation. The asterisk represents significant difference (Two-way ANOVA, P < 0.05).
**Figure 5.** Real-time qRT-PCR confirms the relative expression of genes regulated by PMT12-BF4. *C. albicans* SC5314 cells were grown overnight in liquid YPD at 30 °C, washed twice with ddH2O, and adjusted to 0.25 OD600 with 5 mL fresh YPD in the presence or absence of 1 μg/mL PMT12-BF4. The cultures were incubated at 30 °C for 3 h with shaking at 200 rpm. Cells were collected for total RNA extraction and further real-time qRT-PCR. Significant differences were analyzed using unpaired t test. Asterisks represent significant difference (**P < 0.01; ***P < 0.001).

Our data showed that QAC compounds possess broad-spectrum antifungal activities against pathogenic yeasts and filamentous fungi, and demonstrated best efficacy when there were 12 hydrocarbons in both side chains. The reasons why compounds with 16 hydrocarbon chains are not effective against *C. albicans* and *C. tropicalis*, but effective against *C. glabrata* and *C. neoformans* remain unclear.

A previous report showed that several promising antifungal targets against *C. albicans* were based on iron homeostasis, such as Cfl1 and Fet3. Our RNA sequencing results showed that several genes including iron- or copper-related functions and heme-binding genes (*e.g.*, RBT5, PG A7, CFL2/4/5 etc.) were up-regulated in *C. albicans* under treatment with PMT12-BF4. In addition, several genes in the FET and CFL gene families such as CFL1/2/4/5 and FET3/34 were up-regulated, indicating that PMT12-BF4 may directly or indirectly regulate these gene families. Similar results were also found in *C. albicans* deletion mutant library screening, such that ∆chl2 and ∆fet3 mutants showed resistance to PMT12-BF4, indicating that the mechanisms PMT12-BF4 used to target *C. albicans* might be associated with metal (*i.e.*, iron and copper) ion homeostasis. Previous reports showed that the loss of iron uptake genes such as FET34, a multicopper ferroxidase induced by low iron, could result in a filamentous growth defect in *C. albicans*. In addition, deletion of CFL1, which encodes a protein similar to ferric reductase, decreased cell wall integrity and filamentous growth in *C. albicans*.

As discussed by Puri et al. (2019), iron-related regulation in *C. albicans* is mainly mediated by four regulators, Tup1, Hap43, Sfu1 and Sef1. Our mutant library screening data demonstrated that PMT12-BF4-associated iron-related genes were regulated by these regulators, and most of these genes were repressed by Hap43, indicating the antifungal activity of PMT12-BF4 may not directly alter the iron concentration in the environment, but instead, it possibly interferes with functions of iron regulation. On the other hand, genes associated with hyphal development, biofilm formation and cell wall-related functions were also found from mutant library screening. We noted that an alkaline response-transcription factor mutant rim101 showed resistance to PMT12-BF4, and several genes associated with cell wall integrity were regulated by Rim101, indicating that Rim101 might play a role in mediating the mode of action of PMT12-BF4 against *C. albicans*.

Iron chelators could be used as antifungal agents based on their ability to disrupt iron ion homeostasis and interfere with growth and morphogenesis in *C. albicans*. According to our RNA sequencing data, some genes regulated by PMT12-BF4 can be also upregulated by ciclopirox olamine, an iron chelator. Meanwhile, PMT12-BF4 also showed decreased antifungal activity against *C. albicans* after addition of iron ions, indicating the possibility that the iron uptake activity might be changed when PMT12-BF4 targets the pathogen.

Taken together, the mode of action of PMT12-BF4 against *C. albicans* might involve interrupting cell growth, hyphal development, and biofilm formation, as well as interfering with iron ion homeostasis. In summary, to the best of our knowledge, this is the first report showing that a gemini QAC (*i.e.*, PMT12-BF4) can inhibit *C. albicans* via regulating iron homeostasis, therefore indicating that it might be a novel antifungal agent that could be developed in the future.

**Materials and Methods**

**Strains and media.** The fungal pathogens used in this study are shown in Table 1. The media used in this study were YPD (1% yeast extract [Bioshop, Canada], 2% peptone [Bioshop], 2% dextrose [Bioshop]), PDB (24 g potato dextrose broth [Himedia, India] in 1 L distilled water), RPMI 1640 medium (10.4 g RPMI 1640 powder [Sigma-Aldrich, USA], 34.5 g MOPS [3-(N-morpholino)propanesulfonic acid, Sigma-Aldrich], 2 g dextrose, in 1 L distilled water, with pH adjusted to 7.0 with NaOH), spider medium (10 g nutrient broth [Himedia], 10 g mannoitol [Panreac, Spain], 2 g K2HPO4, in 1 L distilled water, adjusted to pH 7.2 with H2PO4), YNB (0.17% yeast nitrogen base w/o amino acids [Bioshop], 0.5% (NH4)2SO4, 2% dextrose) and modified Dixon medium (36 g malt extract [Merck, Germany], 20 g desiccated ox bile [Sigma-Aldrich], 10 mL Tween 40 [Sigma-Aldrich], 6 g peptone [Bioshop], 2 mL glycerol [Scharlab, Spain], 2 mL oleic acid [Sigma-Aldrich], in 1 L distilled water). All media were solidified by adding 2% agar (Bioshop) if needed, except mDixon medium (1.5% agar).

For synthesis reaction, N, N′, N′′, N′′′-pentamethylidihelynetriamine [Sigma-Aldrich], alkyl bromides [Sigma-Aldrich], 1, 4-butanesultone [Sigma-Aldrich], and acetoni trile [POCH S. A., Poland] were purchased. All compounds were analytical reagent quality and used without further purification.
Synthesis procedures. The synthesis reaction of PMTX-BF4 (X = 12, 16) was carried out in two steps. In the first step, a quaternary amine with a gemini structure (PMTX) was obtained. For this purpose, a reaction was carried out according to the methods described in the literature.26 N, N, N', N'-pentamethyldiethylenetriamine (2 g, 0.01 mol) with the appropriate alkyl bromide (0.02 mol) was heated under reflux for 8–48 h in acetonitrile. The reaction time was extended for bromides with a shorter alkyl chain (Fig. 1). After heating

| ORF          | Gene   | Function                            | Log, fold change |
|--------------|--------|-------------------------------------|------------------|
| CAL0000195131| RFT5   | GPI-linked cell wall protein        | 9.76             |
| CAL0000201731| CFL5   | Ferric reductase; induced in low iron| 8.71             |
| CAL0000185898| CFL4   | C-terminus similar to ferric reductases | 7.53             |
| CAL0000195181| Unknown|                                     | 6.95             |
| CAL0000201827| PGA7   | GPI-linked lyphal surface antigen; heme binding | 5.85             |
| CAL0000192147| Unknown|                                     | 5.83             |
| CAL0000199161| Unknown|                                     | 5.77             |
| CAL0000191531| CFL2   | Oxidoreductase; low iron induced    | 5.15             |
| CAL0000175211| Unknown|                                     | 5.05             |
| CAL0000192466| FET34  | Multicipper ferossidase; low iron induced | 4.27             |
| CAL0000193490| CFL1   | Protein similar to ferric reductase Fre10 | 4.05             |
| CAL0000189382| ZCF4   | Putative Zn(II)2Cys6 transcription factor | 3.33             |
| CAL0000187683| FRP1   | Ferric reductase; iron chelation induced by CCAAT-binding factor | 3.44             |
| CAL0000186938| FTH1   | Iron transporter for intravacuolar stores of iron | 3.35             |
| CAL0000177334| FRE10  | Cell-surface ferric reductase under low-iron conditions | 3.13             |
| CAL0000177342| PCL1   | Cyclin-dependent protein kinase regulator | 2.76             |
| CAL0000187845| Vacular membrane transporter for cationic amino acids | 2.73             |
| CAL0000179600| Unknown|                                     | 2.56             |
| CAL0000201164| RTA4   | Fatty acid transport; caspofungin induced | 2.53             |
| CAL0000185936| Unknown|                                     | 2.51             |
| CAL0000197324| FET3   | Putative multicopper oxidase         | 2.50             |
| CAL0000190583| XOG1   | Eko-1,3-beta-glucanase; Hap43-induced in low iron condition | 2.46             |
| CAL0000176590| DDR48  | Immunogenic stress-associated protein | 2.30             |
| CAL0000190984| CDC6   | Putative ATP-binding protein; Mcm1 regulon | 2.27             |
| CAL0000176514| Unknown|                                     | 2.27             |
| CAL0000180057| Unknown|                                     | 2.24             |
| CAL0000188488| Unknown|                                     | 2.20             |
| CAL0000191729| ECM331 | GPI-anchored protein                | 2.17             |
| CAL0000175827| IFD6   | Protein with a NADP-dependent oxidoreductase domain | 2.10             |
| CAL0000185357| Unknown|                                     | 2.08             |
| CAL0000179271| Putative proton coupled folate transporter/heme carrier | 2.07             |
| CAL0000179373| CPD2   | Protein with homology to NADH dehydrogenase | 2.05             |
| CAL0000190667| Unknown|                                     | 2.02             |
| CAL0000178375| Unknown|                                     | 2.01             |

Table 3. Genes regulated in C. albicans SC5314 after PMT12-BF4 treatment.
was complete, the product was crystallized, filtered and dried from the solution. The gemini surfactant obtained from the first step was then reacted with tetrafluoroboric acid in a 1:1 molar ratio, proceeding with ion exchange (Fig. 1b). The obtained crystalline (PMTX-BF4) was washed with ethanol to remove unreacted substrates. The products' NMR, IR and elemental analysis results are given below:

**PMT12-BF4.**  
1, 5-bis(dodecyl)-1, 1, 3, 5, 5-pentamethyl-3-aza-1, 5-pentanediammonium ditetrafluoroborate

1H NMR (CDCl3) \( \sigma = 0.889 \) (6 H, \( 2 \times CH_3 \)), 1.265 (36 H, \( CH_2 \)), 1.746 (4 H, \( CH_2 \)), 2.634 (3 H, \( CH_3 \)), 3.180 (12 H, \( 4 \times CH_3 \)), 3.336 (8 H, \( 4 \times CH_2N^+ \)), 3.734 (4 H, \( CH_2N \)).

13C NMR (CDCl3) \( \sigma = 14.242 \) (2 \( CH_3 \)), 22.689 (2 \( CH_2 \)), 26.189 (4 H, \( CH_2N^+ \)), 29.228 (2 \( CH_3 \)), 29.371 (2 \( CH_2N^+ \)), 31.922 (2 \( CH_2N^+ \)), 41.475 (CH3), 50.056 (2 \( CH_3N^+ \)), 59.363 (2 \( CH_2N^+ \)), 65.907 (2 \( CH_2N^+ \)).

IR: 2917, 2850, 1467, 1030.

**PMT16-BF4.**  
1, 5-bis(hexadecyl)-1, 1, 3, 5, 5-pentamethyl-3-aza-1, 5-pentanediammonium ditetrafluoroborate

1H NMR (CDCl3) \( \sigma = 0.911 \) (6 H, \( 2 \times CH_3 \)), 1.288 (52 H, \( CH_2 \)), 1.766 (4 H, \( CH_2 \)), 2.715 (3 H, \( CH_3 \)), 3.195 (12 H, \( 4 \times CH_3 \)), 3.390 (8 H, \( 4 \times CH_2N^+ \)), 3.784 (4 H, \( CH_2N \)).

13C NMR (CDCl3) \( \sigma = 14.266 \) (2 \( CH_3 \)), 22.709 (2 \( CH_2 \)), 26.194 (2 \( CH_2N^+ \)), 29.252 (2 \( CH_3 \)), 29.375 (2 \( CH_2N^+ \)), 29.778 (18 \( CH_2N^+ \)), 31.942 (2 \( CH_2N^+ \)), 41.474 (CH3), 49.991 (2 \( CH_3N^+ \)), 50.775 (4 \( CH_3N^+ \)), 59.277 (2 \( CH_2N^+ \)), 66.164 (2 \( CH_2N^+ \)).

IR: 2915, 2849, 1469, 1037.

**Determination of the antifungal activity of the compound.**  
Two compounds, PMT12-BF4 and PMT16-BF4 were tested in this study. The stock solutions were prepared by dissolving each compound powder in distilled water or dimethyl sulfoxide (DMSO, [Scharlab, Spain]) at a concentration of 5 mg/mL, and then they were kept at room temperature for further use.

To determine the antimicrobial activity, we followed the Clinical and Laboratory Standards Institute (CLSI) guidelines M27-A3 for yeasts and M38-A2 for filamentous fungi. In brief, 100 \( \mu L \) of serially diluted compounds (2-fold the final concentration) were added into 100 \( \mu L \) cells or conidia suspensions in a 96-well polystyrene plate (Nest Biotechnology, China). The final cell concentrations were 1.25 \( \times 10^3 \) CFU/mL for yeasts, or 2.5 \( \times 10^4 \) conidia/mL for filamentous fungi, while the final concentrations of tested compounds ranged from 0.125 to 64 \( \mu g/mL \). The plates were incubated for 48 h at 35 °C without shaking. When conducting this assay for *Malassezia furfur*, a yeast pathogen isolated from human dandruff, the protocol was modified slightly: mDixon medium was used and the plate was incubated at 35 °C for 7 days. The minimal inhibitory concentration (MIC) was defined as the lowest concentration showing no visible growth. For fluconazole and micafungin against *C. albicans*, MIC was defined as the lowest concentration for which a prominent decrease in turbidity is observed (approximately 50% decrease as determined visually or spectrophotometrically) as described in the CLSI protocol. Minimal fungicidal concentration (MFC) was determined after the MIC test. For each strain, 3 \( \mu L \) of wells containing compounds at concentrations from 0.5 MIC (positive control) to the highest concentration (64 \( \mu g/mL \)) were
pipetted up and down thoroughly and subcultured onto drug-free YPD agar plates. The plates were incubated at an optimal temperature for growth of each fungal pathogen for 48 h and the MFC was determined as the drug concentration at which no colonies formed.

**Time-killing kinetic assay.** Overnight cultures of *C. albicans* SC5314 were washed twice with ddH2O and inoculated into YPD broth to a volume of 3 mL (10⁵ CFU/mL) with or without 4 μg/mL PMT12-BF4. The cultures were incubated at 30 °C. At the indicated time points (0, 4, 8, 12, 24 and 48 h), a 100 μL aliquot was removed from each culture and appropriately diluted with ddH2O. A 100 μL diluted aliquot was then plated on a fresh YPD agar plate and incubated at 37 °C for 24 h before colony count.

**Growth kinetics assay.** *C. albicans* cells were grown overnight in YPD at 30 °C, and diluted to a concentration of 1.25 × 10⁴ CFU/mL in 200 μL YPD with 2-fold serial diluted compounds ranging from 0.125 to 64 μg/mL in a 96-well plate. Medium without compounds was used as a positive control, while that without inoculum served as a negative control. The plate was incubated at 30 °C, and OD₆₀₀ was measured at the following time points (0, 2, 4, 6, 8, 10, 12, 24 and 48 h) after incubation. Every well was mixed thoroughly with a pipette before spectrometric measurement. The average optical density (OD) value of the negative control wells was subtracted from that of each experimental and positive control well. To calculate the relative growth, wells without compounds at 48 h were set as 100% growth compared to the initial OD value at 0 h.

**Germ tube induction assay.** *C. albicans* SC5314 cells were cultured in YPD broth overnight at 30 °C, washed twice with ddH₂O and diluted with 1 mL RPMI 1640 medium to OD₆₀₀ 0.25 in a 12-well plate (Nest Biotechnology, China). PMT12-BF4 was then added into wells at the concentrations of 0, 0.25, 0.5 or 1 μg/mL with three replicates. The plate was incubated at 37 °C for 3 h for germ tube induction, and observed with an inverted microscope (Olympus, Japan) at 400X magnification. Cells were photographed by a camera connected with Olympus cellSens Entry 2.1 software.

**Biofilm formation assay.** Biofilm formation assay was conducted with slight modification as described previously²⁸⁻²⁹. In brief, *C. albicans* cells were grown overnight in YPD at 30 °C, diluted to a 0.5 OD₆₀₀ in 2 mL Spider medium in a 12-well plate (Falcon, flat bottom and non-cell tissue treated). The plates were incubated at 37 °C for 2 h at 150 rpm agitation for initial adhesion of cells. The plates were washed with 2 mL PBS, and 2 mL of Spider medium was added with PMT12-BF4 at the indicated concentrations (0, 1, 2 or 4 μg/mL). The plates were incubated at 37 °C for 24 h at 150 rpm agitation to allow biofilm formation. After incubation, the plates were washed twice with 2 mL PBS, and stained with 2 mL 0.4% crystal violet for 45 min. After washing with ddH₂O, wells were destained with 2 mL 95% EtOH for 45 min. The content (200 μL) of each well was transferred to a new 96-well plate with appropriate dilutions, and the optical density was measured at a wavelength of 595 nm. The mean OD₅₉₅ value of negative control wells (without inoculum) was subtracted from that of each experimental and positive control well (without compound), and all values were then normalized to the mean value of positive
control wells. The biofilm formation of wells without PMT12-BF4 was set as 100%. Statistical analyses (Student's unpaired two-tailed t test) were performed with GraphPad Prism 6.0 software. Significance was set as a P value less than 0.05.

**Scanning electron microscopy.** Cultures of *C. albicans* grown overnight at 30 °C in YPD medium were harvested and washed twice with PBS. The cells were resuspended in 3 mL of RPMI 1640 medium with PMT12-BF4 at the indicated concentrations (0, 0.5, 1, or 2 μg/mL), adjusted to 10^5 CFU/mL, and incubated at 37 °C for 3 h. After the incubation, cells were washed twice with PBS and fixed overnight in 2.5% glutaraldehyde in 0.1 M phosphate buffer. The samples were washed three times with 0.1 M phosphate buffer, each for 10 min, and post-fixed in 1% osmium tetroxide (OsO4) for 1 h. The post-fixed cells were washed 3 times with 0.1 M phosphate buffer to remove OsO4, and then dehydrated in ethanol in a 30% to 100% gradient (once at 30%, 50%, 70%, 85%, 90%, and 95%, each for 10 min; twice at 100% for 20 min) and 100% acetone for 10 min. The samples were thoroughly dried in a critical point dryer with liquid CO2 (Hitachi HCP-2, Japan) and coated with gold using an ion coater (Eiko Engineering, Japan). After processing, samples were observed and photographed in a scanning electron microscope (FEI Inspect S, USA).

**RNA sequencing experiments.** *C. albicans* SC5314 cells were grown overnight in liquid YPD at 30 °C, washed twice with ddH2O, and adjusted to OD600 0.25 with 5 mL fresh YPD in the presence or absence of 1 μg/mL PMT12-BF4. The cultures were incubated at 30 °C for 3 h with shaking at 200 rpm. Cells were centrifuged at 4 °C for 10 min at 3,250 rpm, and washed with ice-cold ddH2O to discard the medium. Total RNA was extracted using TRIzol reagent (Invitrogen, USA). Collected cells were frozen in liquid N2, and vortexed with beads. After adding 1 mL TRIzol, cultures were centrifuged at 4 °C/12,000 g for 10 min, and the supernatant was transferred to a new tube. After incubation for 5 min at room temperature, 200 μL of chloroform was added and mixed thoroughly, and tubes were incubated at room temperature for 3 min, centrifuged at 4 °C/12,000 g for 15 min, and the supernatant was transferred to a new tube. Isopropanol (500 μL) was added to the tubes, incubated at room temperature for 10 min, centrifuged at 4 °C/12,000 g for 10 min, and the supernatant was discarded. The pellet containing RNA was washed twice with 75% ethanol and resuspended with RNAase free water.

The Next Generation Sequencing (NGS) library construction using RNA was as described in a previous study30. The mRNA was enriched with oligo(dT) magnetic beads and shortened into approximately 200-base fragments in fragmentation buffer. The first strand of cDNA was synthesized by the use of a random hexamer, buffer, dNTPs, and RNase H, and the second strand by the use of DNA polymerase I. The double strand cDNAs were purified with magnetic beads. After end preparation and 3′ end single nucleotide adenine addition were performed, sequencing adaptors were ligated to the fragments, and amplified by PCR. An Agilent 2100 bioanalyzer and ABI StepOnePlus real-time PCR system were used to qualify and quantify the sample library, and the library products were sequenced via an Illumina HiSeq. 2000 instrument.

**Real-time qRT-PCR.** Real-time qRT-PCR was conducted as in a previous study30. Total RNA extracted as described above was treated with a Turbo DNA-free kit (Invitrogen, Carlsbad, CA, USA) following the manufacturer’s protocol to eliminate genomic DNA contamination, and 2 μg of DNA-free total RNAs were reverse transcribed to cDNA using a high capacity cDNA reverse transcription kit (Applied Biosystems). A 10-μL reaction volume of the real-time PCR mixtures included 1 μL of cDNA (5 ng), 5 μL of 2 × Fast SYBR green master mix (Applied Biosystems), 0.5 μL of 10 μM forward primer, and 0.5 μL of 10 μM reverse primer. Primer pairs used in real-time PCR are listed in Supplementary Table 2. Quantitative PCR conditions were set as follows: 95 °C for 10 min for denaturation, 95 °C for 15 s and 60 °C for 60 s (40 cycles), 95 °C for 15 s, 95 °C for 60 s, and 95 °C for 15 s (melting curve). Cycle threshold (Ct) values were determined by a StepOnePlus system and StepOne software (v2.3), and the relative gene expressions were calculated based on ACT1-calibrated and 2^−ΔΔCt values. The relative expression levels of *C. albicans* genes in the presence of 1 μg/mL PMT12-BF4 were normalized to those in the absence PMT12-BF4, and the bar graphs were obtained using GraphPad Prism 6.0 software. Significant differences were analyzed using unpaired t test (P < 0.05).

**Mutant library screening.** The homozygous knockout mutant set of *C. albicans* was purchased from the Fungal Genetics Stock Center (http://www.fgsc.net/candida/FGSCandidaresources.htm), and used to screen potential target(s) of PMT12-BF413. The set contained 666 homozygous mutants and two *C. albicans* SN152 wild-type strains derived from strain SC5314 with auxotroph of histidine, leucine, and arginine. Among these mutants, 316 (approximately 47%) genes were characterized. For library screening, 100 μL of YPD with 4 μg/mL PMT12-BF4 was added into a 96-well plate, and the inoculum was transferred from stock plates of knockout mutant sets with a sterile replica plater. The inoculated plates were incubated at 30 °C for 24–48 h without shaking and mutants showing visible growth in wells were defined as resistant strains against PMT12-BF4.

**Determination of cell toxicity of PMT12-BF4.** The human neuroblastoma cell line SK-N-SH was cultured in Dulbecco’s modified Eagle’s medium (DMEM, Hyclone, USA), and the human embryonic kidney cell line HEK293 was cultured in minimum essential medium (MEM, Gibco, USA). Both media contained 10% fetal bovine serum (Corning, USA), 2 mM L-glutamine (Hyclone, USA), and antibiotic solution of 100 U/mL penicillin G, 100 μg/mL streptomycin, 0.25 μg/mL amphotericin B. Both SK-N-SH and HEK293 cells were incubated at 37 °C under 5% CO2 and passed every 3–4 days.

Cell viability was assessed by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide [MTT (Thiazolyl Blue Tetrazolium Bromide, Sigma, USA)] cell viability assay in triplicate. SK-N-SH cells were seeded at a density of 2.5 × 10^4 cells/mL in a 96-well plate (200 μL/well), and HEK293 cells were seeded at a density of 10^5 cells/mL.
in a 24-well plate (500μl/well) for 24 h before PMT12-BF4 treatment at 37 °C under 5% CO2. Subsequently, SK-N-SH cells were treated with 0, 1, 2, 3, 4, 5, 6, 8, 12, and 16μg/ml PMT12-BF4, while HEK293 cells were treated with 0, 1.25, 2.5, 5, 10, and 20μg/ml PMT12-BF4, and plates were incubated at 37 °C under 5% CO2 for 24 h. After the treatment, cells were incubated with MTT solution at a concentration of 5mg/ml for 2 h at 37 °C under 5% CO2. After removal of the medium, 200μl of DMSO was added for optical density (OD) measurement at 575 nm using a spectrophotometer (SpectraMax 190 UV-Vis Microplate, Molecular Devices, USA). The percentages of viable cells were calculated as [(sample OD575 nm) – (blank OD575 nm)]/[(control OD575 nm) – (blank OD575 nm)] × 100(%).

Data availability
We deposited the RNA sequences in the NCBI Gene Expression Omnibus (GSE) database under accession number GSE129191 (https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE129191, token: apkjyqjsh0nxwd).

References
1. Chang, Y. L., Yu, S. J., Heitman, J., Wellington, M. & Chen, Y. L. New facets of antifungal therapy. Virulence 8, 222–236, https://doi.org/10.1080/21505594.2016.1257457 (2017).
2. Lee, C. Structure, conformation, and action of neuromuscular blocking drugs. Br. J. Anaesth. 87, 755–769 (2001).
3. Xiao, Y. H. et al. Antibacterial effects of three experimental quaternary ammonium salt (QAS) monomers on bacteria associated with oral infections. J. Oral. Sci. 50, 323–327 (2008).
4. Grant, W. M. A study of the actions of nonaromatic quaternary ammonium compounds on the eye. Trans. Am. Ophthalmol. Soc. 54, 417–451 (1956).
5. Rodrigo, G., Rodrigo, C. & Rurschtein, O. A meta-analysis of the effects of ipratropium bromide in adults with acute asthma. Am. J. Med. 107, 363–370 (1999).
6. Obalci, E. & Gamian, A. The biological activity of quaternary ammonium salts (QASs). Postepy Hig. Med. Dosw 64, 201–211 (2010).
7. McDonnell, G. & Russell, A. D. Antisepsics and disinfectants: activity, action, and resistance. Clin. Microbiol. Rev. 12, 147–179 (1999).
8. Qibin, C. et al. Cationic Gemini surfactant at the air/water interface. J. Colloid Interface Sci. 314, 651–658, https://doi.org/10.1016/j.jcis.2007.05.063 (2007).
9. Rosen, M. J. Surfactants and interfacial phenomena. Third edn. (John Wiley & Sons, Inc., 2004).
10. Zana, R. Dimeric and oligomeric surfactants. Behav. interfaces aqueous solution: a review. Adv. Colloid Interface Sci. 97, 205–253 (2002).
11. Murguía, M. C., Machuca, L. M., Lurá, M. C., Cabrera, M. I. & Grau, R. J. Synthesis and properties of novel antifungal gemini compounds derived from N-acetyl diethanolamines. J. Surfactants Detergents 11, 223–230, https://doi.org/10.1007/s11743-008-1076-4 (2008).
12. Zielinski, R. Surfałkanty. Budowa, właściwości, zastosowania. (Wydawnictwo Uniwersytetu Ekonomicznego, 2009).
13. Noble, S. M., French, S., Kohn, L. A., Chen, V. & Johnson, A. D. Systematic screens of a Candida albicans homozygous deletion library decouple morphogenetic switching and pathogenicity. Nat. Genet. 42, 590–598, https://doi.org/10.1038/ng.805 (2010).
14. Tawfik, S. M. Synthesis, surface, biological activity and mixed micellar phase properties of some biodegradable gemini cationic surfactants containing oxycarboxyl groups in the lipophilic part. J. Ind. Eng. Chem. 28, 171–183, https://doi.org/10.1016/j.jiec.2015.02.011 (2015).
15. Bao, Y., Guo, J., Ma, J., Li, M. & Li, X. Physicochemical and antimicrobial activities of cationic gemini surfactants with polyether silylamine linked group. J. Mol. Liq. 242, 8–15, https://doi.org/10.1016/j.molliq.2017.06.049 (2017).
16. Bustelo, M. et al. Monocatenary histidine-based surfactants: Role of the alkyl chain length in antimicrobial activity and their selectivity over red blood cells. Colloids Surf. A: Physicochemical Eng. Asp. 532, 501–509, https://doi.org/10.1016/j.colsurfa.2017.04.017 (2017).
17. Li, Y. et al. Promising antifungal targets against Candida albicans based on ion homeostasis. Front. Cell. Infect. microbiology 8, 286–286, https://doi.org/10.3389/fcimb.2018.00286 (2018).
18. Cheng, X. et al. Novel insight into the expression and function of the multicopper oxidases in Candida albicans. Microbiology 159, 1044–1055, https://doi.org/10.1099/mic.0.065268-0 (2013).
19. Mamouei, Z., Zeng, G., Wang, Y. M. & Wang, Y. Candida albicans possess a highly versatile and high-difficulty iron transport system important for its commensal-pathogenic lifestyle. Mol. Microbiology 106, 986–998, https://doi.org/10.1111/mmi.13864 (2017).
20. Xu, N. et al. Novel role of the Candida albicans ferric reductase gene CFL1 in iron acquisition, oxidative stress tolerance, morphogenesis and virulence. Res. Microbiology 165, 252–261, https://doi.org/10.1016/j.resmic.2014.03.001 (2014).
21. Yu, Q. et al. A novel role of the ferric reductase CFL1 in cell wall integrity, mitochondrial function, and invasion to host cells in Candida albicans. FEMS Yeast Res. 14, 1057–1047, https://doi.org/10.1111/femsy.12184 (2014).
22. Puri, S., Kumar, R., Rojas, J. G., Salvatori, O. & Edgerton, M. Iron chelator deferasirox reduces Candida albicans invasion of oral epithelial cells and infection levels in murine oralophyngyal candidiasis. Antimicrobial Agents Chemotherapy 63, e02152–e02118, https://doi.org/10.1128/AAC.02152–018 (2019).
23. Tripathi, S. K. et al. Two plant-derived aporphinoid alkaloids exert their antifungal activity by disrupting mitochondrial iron-sulfur cluster biosynthesis. J. Biol. Chem. 292, 16578–16593, https://doi.org/10.1074/jbc.M117.781773 (2017).
24. Prasad, T. Chandra, A., Mukhopadhyay, C. K. & Prasad, U. Unexpected link between iron and drug resistance of Candida spp.: iron depletion enhances membrane fluidity and drug diffusion, leading to drug-susceptible cells. Antimicrobial agents chemotherapy 50, 3597–3606, https://doi.org/10.1128/AAC.00653-06 (2006).
25. Niewerth, M. et al. Ciclopirox olamine treatment affects the expression pattern of Candida albicans genes encoding virulence factors, iron metabolism proteins, and drug resistance factors. Antimicrobial agents chemotherapy 47, 1805–1817, https://doi.org/10.1128/AAC.47.6.1805–1817.2003 (2003).
26. Wetig, S. D., Wang, C., Verrall, R. E. & Foldvari, M. Thermodynamic and aggregation properties of aza- and imino-substituted gemini surfactants designed for gene delivery. Phys. Chem. Chem. Phys. 9, 871–877, https://doi.org/10.1039/B613269C (2007).
27. Leong, C., Buttafuco, A., Glatz, M. & Bosshard, P. P. Antifungal susceptibility testing of Malassezia spp. with an optimized colorimetric broth microdilution method. J. Clin. Microbiol. 55, 1883–1893, https://doi.org/10.1128/JCM.00338–17 (2017).
28. Noble, C. et al. A recently evolved transcriptional network controls biofilm development in Candida albicans. Cell 148, 126–138, https://doi.org/10.1016/j.cell.2011.10.048 (2012).
29. Lobse, M. B. et al. Assessment and optimizations of Candida albicans in vitro biofilm assays. Antimicrob Agents Chemoteraphy 61, https://doi.org/10.1128/AAC.02749–16 (2017).
30. Yu, S. J., Chang, Y. L. & Chen, Y. L. Deletion of ADA2 increases antifungal drug susceptibility and virulence in 
Candida glabrata. Antimicrob Agents Chemother 62, https://doi.org/10.1128/AAC.01924-17 (2018).
31. Odds, F. C., Brown, A. J. & Gow, N. A. Candida albicans genome sequence: a platform for genomics in the absence of genetics. 
Genome Biol. 5, 230, https://doi.org/10.1186/gb-2004-5-7-230 (2004).
32. White, T. C. Increased mRNA levels of ERG16, CDR, and MDRI correlate with increases inazole resistance in 
Candida albicans isolates from a patient infected with human immunodeficiency virus. Antimicrob. Agents Chemother. 41, 1482–1487 (1997).
33. Garcia-Effron, G., Park, S. & Perlin, D. S. Correlating echinocandin MIC and kinetic inhibition of 
fks1 mutant glucan synthases for 
Candida albicans: implications for interpretive breakpoints. Antimicrob. Agents Chemother. 53, 112–122, https://doi.org/10.1128/ 
AAC.01162-08 (2009).
34. Butler, G. et al. Evolution of pathogenicity and sexual reproduction in eight Candida species. Nat. 459, 657–662, https://doi. 
org/10.1038/nature08064 (2009).
35. Dujon, B. et al. Genome evolution in yeasts. Nat. 430, 35–44, https://doi.org/10.1038/nature02579 (2004).
36. Perfect, J. R., Ketabchi, N., Cox, G. M., Ingram, C. W. & Reiser, C. L. Karyotyping of Cryptococcus neoformans as an epidemiologic 
tool. J. Clin. Microbiol. 31, 3305–3309 (1993).
37. Castella, G., Coutinho, S. D. & Cabanes, F. J. Phylogenetic relationships of Malassezia species based on multilocus sequence analysis. 
Med. Mycol. 52, 99–105, https://doi.org/10.1185/13693786.2013.815372 (2014).
38. Nierman, W. C. et al. Genomic sequence of the pathogenic and allergenic filamentous fungus Aspergillus fumigatus. Nat. 438, 1151–1156, 
https://doi.org/10.1038/nature04332 (2005).
39. O’Donnell, K. et al. Genetic diversity of human pathogenic members of the Fusarium oxysporum complex inferred from multilocus 
DNA sequence data and amplified fragment length polymorphism analyses: evidence for the recent dispersal of a geographically 
widely spread clonal lineage and nosocomial origin. J. Clin. Microbiol. 42, 5109–5120, https://doi.org/10.1128/JCM.42.11.5109- 
5120.2004 (2004).
40. Ma, L. J. et al. Comparative genomics reveals mobile pathogenicity chromosomes in Fusarium. Nat. 464, 367–373, https://doi. 
or/10.1038/nature08850 (2010).

Acknowledgements
We are grateful to Miranda Loney for language editing and Technology Commons, College of Life Science, 
National Taiwan University (Taiwan) for SEM observation. This work was financially supported by grants 
106-2923-B-002-001-MY3, 107-2923-B-002-001-MY3 from the Ministry of Science & Technology in Taiwan 
and grant PL-TW IV/2/2017 from the National Centre of Research and Development in Poland.

Author contributions
L.H.H. designed and performed experiments; analyzed and interpreted data and wrote the manuscript. D.K. 
synthesized Gemini quaternary ammonium compounds and wrote the manuscript. SCW performed experiments 
and grant PL-TW IV/2/2017 from the National Centre of Research and Development in Poland.

Competing interests
The authors declare no competing interests.

Additional information
Supplementary information is available for this paper at https://doi.org/10.1038/s41598-020-59750-5.

Correspondence and requests for materials should be addressed to D.W. or Y.-L.C.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and 
institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International 
License, which permits use, sharing, adaptation, distribution and reproduction in any medium or 
format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Cre- 
vative Commons license, and indicate if changes were made. The images or other third party material in this 
article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the 
material. If material is not included in the article’s Creative Commons license and your intended use is not per- 
mitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the 
copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2020